Bob Bradway, Amgen CEO (Justin Kase Conder/AP Images for Amgen)
May 9, 2023 11:08 AM EDT
Deals

Am­gen en­lists TCR start­up TScan to work on Crohn's in deal po­ten­tial­ly worth $500M+

Max Gelman

Senior Editor

Am­gen is tak­ing a clos­er look at us­ing T cells for in­flam­ma­tion, an­nounc­ing a new deal Tues­day with TCR up­start TScan Ther­a­peu­tics.

The com­pa­nies will …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Vac­cine biotechs say they’ve been told to stop next-gen Covid work un­der a Biden-era project

Re­cent FDA staff cuts to de­lay drug hear­ing de­ci­sion by months, agency tells Van­da

Drug­mak­ers stock­pile in­ven­to­ry in the US, seek­ing to get ahead of Trump tar­iffs

Up­dat­ed: Roche’s $50B US in­vest­ment in­cludes pre­vi­ous build an­nounce­ments

Re­gen­eron to boost its US man­u­fac­tur­ing through a $3B Fu­ji­film deal

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times